Untitled

Abstract

The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn's disease has been evaluated. Thirty-two patients with Crohn's disease in clinical remission (CDAI < 150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn's disease. However, in view of the product's cost, further controlled studies are needed to confirm these preliminary data.

Saccharomyces boulardii Inhibits ERK1/2 Mitogen-activated Protein Kinase Activation Both in Vitro and in Vivo and Protects against Clostridium difficile Toxin A-induced Enteritis

“…Sb may also be useful in preventing clinical relapse in Crohn disease (11). However, the mechanisms whereby Sb exerts its beneficial effects have not been fully characterized.…”

Formulations for Protecting the Probiotic Saccharomyces boulardii from Degradation in Acidic Condition

“…(Fig. 5) The viability of the control sample of non-tabletted freeze-dried (FD) yeast (batch 6) in 0.1 N HCl decreased significantly from 2.6Ϯ0.2ϫ10 10 to 7.9Ϯ2.5ϫ10 9 cfu/g of yeast in the first 5 min (pϽ0.05 vs. time 0) and was less than 1% of viable yeast after 120 min (4.0Ϯ3.6ϫ10 5 cfu/g, pϽ0.05 vs. time 0). The initial release of viable yeasts from tablets (79Ϯ6 N) in 0.1 N HCl was fast and reached a maximum value of 1.54Ϯ0.28ϫ10…”

“…No disintegration occured in HCl, the release of viable yeasts was partial (Ͻ1%) in this medium and achieved a relative plateau up to 120 min. In pH 6.8 phosphate buffer solution, disintegration of the tablet occured after 60 min and the progressive release of viable yeast led to a total of 1.41Ϯ0.12ϫ10 9 cfu/g at 240 min, which corresponds to a 30% loss of viability compared to the initial content of viable yeasts in the matrix tablets.…”

“…[1][2][3][4][5][6][7] Besides its use as an anti-diarrhoeal agent, 8) S. boulardii also exhibits beneficial effects on other intestinal pathologies like Crohn's disease 9) and ulcerative colitis. 10) As a living microorganism interacting with the intestinal microflora, S. boulardii is considered as a probiotic according to the definition of the World Health Organization, i.e.…”

Administration of Antibiotics during Infancy Promoted the Development of Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice

“…13) These indigenous bacteria play major roles in the maturation of the immune system, maintenance of homeostasis of the gut-associated immune system, [14][15][16] and the induction of oral tolerance. [17][18][19] Because oral administration of broad-spectrum antibiotics depletes normal commensal microbiota as they target microbial pathogens, it is hence speculated that depletion of microbiota by antibiotics is associated with increased risk for the development of allergy. Oyama et al 20) reported that oral administration of kanamycin during infancy, but not in adulthood, promoted a shift in the TH1/TH2 balance toward TH2-predominant immunity in mice.…”